Five down days in a row? This is starting to look like the breakout that wasn't.
I think AMGN might have reached its upward limit and that a pullback may be possible. I started receiving notifications from Awe-Some.Sto-ck.s the other week and so far they have presented interesting new trade ideas.
The scenarios are quite interesting at current levels for AMGN. Ive been struggling with this stock lately. Some of my other trades have been from awesom_sto-cks which are working out pretty well.
from sa advisory
On Sept 14, 2017 key personal will discuss the advancements of ARWR and also the joint venture with AMGN. To recap~ ARWR will provide an overview of the Company's new platform technology and its pipeline of RNAi- based therapeutics. This discussion will include:
1. The targeted RNAi Molecule (TRiM) Platform, which includes targeted to the liver, tumors, and another tissue to be disclosed at the event.
2.ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency,
3. ARO-HBV for chronic hepatitis B infection
4. ARO-APOC3 for cardiovascular diseases
5. Updates on ARWR's clinical development timelines
Please recall back on Sept 29th 2016 ARWR/AMGN created a Cardiovascular Collaboration for 2 RNAi therapeutics. The Total deal value of up to $673.5 million. ARWR received $56 million up front. The herd will have "big ears" concerning the outcome of this collaboration. Via the grapevine there has been chatter that both companies will be formally introducing a FDA filing on potential drug testing . If the mere mention of this advanced FDA process they herd will have a bullish stampede on the upside and shorts will hang themselves if they can even afford the rope!
Biotechs are the toughest investment speculation to be found anywhere. If cash burn-rate was not hard enough to swallow you then need to deal with "gods" of the FDA! Fortunes can be had as well as potentially vying for an abandoned shopping cart.
Like a "hurricane" the FDA can clip millions or billions off the value of a company's market-cap with a 4 letter word-"DENY"!
Last November 2016 the FDA "clipped" ARWR when the Arrow's lab somehow OD'd a few chimps and regardless how successful the human trial had gone- the FDA punished ARWR causing the stock to free fall from $6.00 to $1.20! Faster than a hand of Blackjack !
At the same time AMGN decided to throw ARWR a small bone with the possibility of a large Dinosaur bone ($622,000,000.00) if results from a new platform could create a Cardio cancer drug. At present AMGN is funding the company for their research with more money to be released if results are juicy enough!
We still believe that ARWR is still deep into their RNAi based therapeutic platform. In a nutshell RNAi is the mechanism that offers a pathway of gene silencing to target and shut down specific genes that cause disease.
Note: go to www.amgenscience.com and click,"the shape of drugs and go down and click RNAi. There is more than meet the eye between AMGN/ARWR.
The large sum of money mentioned above with AMGN deals with a program to utilize ARWR's proprietary subcutanous RNAi delivery platform for therapies for cardiovascular disease. Part of the agreement grants AMGN worldwide, exclusive license to ARWR's novel, RNAi-ARC-LPA program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease.
In our opinion, if AMGN continues to like the results i see very little reason why AMGN would continue to fund the company, but instead just buy them.
ARWR is extremely rich with patents, technology and capable science so AMGN gets many valuable extras. Lately, the Biotech segment has been active in the M&A area -KITE was just swallowed by Gilead for $12 billion! Many of these Biotech's are swimming with hordes of cash and i believe Gilead has just woken up the major players to start grabbing deals before the other guy snags them!
AMGN is a "GOD" of the Biotech sector. At present they have $39,000,000,000 in cash and their stock is $180.00/sh and there are around 730 million shares outstanding.
The fantasy: Amgen buys ARWR for $20/sh because the results announced on Sept 14th and beyond indicate enormous potential. If AMGN paid cash that would only be $1.5 Billion. Personally, if i was AMGN i would use their stock and it would only cost around 8.3 million shares of AMGN stock. Like a drop of water in a puddle.
Food for thought: Silence Therapeutics owns over 9% of ARWR free trading shares.
The company is heavy into RNAi research and development.
We have been involved in ARWR for a number of years and have felt the euphoria and level 9 of HELL!
ARWR has been involved with Gilead (GILD-$85) ,Novartis (NVS-$86) and Amgen (AMGN-$180).
It is only a matter of time before one of these giants takes out ARWR because of their results, platforms, science, patents and most importantly results. We rate ARWR with a strong buy rating. It maybe like playing dice, but in our case even if you throw a snake eyes we still have the potential to throw 7 at a later date.
On Sept 14, 2017 the cards will be on the table. There will be 3 options: 1.the street already assumed the steady potential with AMGN and the stalls and the short lick their chops!
2. Results are less than anticipated and the stocks drops to low $2 range even though AMGN continues the research and still will fund.
3. We hit certain milestones and results are very favorable and the stock rockets!
Regardless, we believe a good price ($3.39) to build a position in this biotech opportunity with amazing upside potential .
$ARWR $GILD $AMGN $NVS
Amgen in a funk today? Anybody have any insight.
Who says AMGN isn't poised for potentially massive upward movement? check out https://activepennystocks1.blogspot.com, its a pretty reliable service. of course you have to do your own due diligence, but they generally point you in the right direction.
What going with AMGN? Is there some bad news?
Aren't you glad you own AMGN? Paid about 46 in 1990's. Glad I did.
Wall Street Best Biotech Investment Advisor Portfolio Soars to All-Time Highs
https://stockmarketLIVE.TV stock market Live News. Live streaming trading. Live stock forecasts. Trading Courses. Live Earnings Calls. Markets Live Analysis....
Look for heavy profit taking after yesterdays gains.
Trump got a loose FDA
According to Nasdaq, analysts have the following estimates for ENDP:
(18)$3.09 (19)$3.45 (20)$3.94
If ENDP just trades at 6x forward estimates, ENDP is a $22-24 stock. Finally, it's also important to note that ENDP's management recently guided 20 new drug launches for 2017 and over 20 new regulatory drug filings for this fiscal year. Good luck to all 🐻
SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M / 17 FDA approved products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..GLTA
Sonoma Pharma (Nasdaq: SNOA)
Market Cap: 22.1 Million Cash: $12.6 Million Price: $5.15
Driving to commercial EBITDAS breakeven, without dilution
Grow current product portfolio with all sales people
•Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment •Mondoxyne for severe acne –launched late 2015 •Ceramax for skin repair in atopic dermatitis–launched in April 2016 •SebuDerm for seborrhea dermatitis –launched in November 2016
Launch 3 New Products –our product pipeline –one every other quarter
•Launching Loyon–Fall 2017 •Ceramax in foam and gel forms –Q4 2017 & Q1 2018
Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.
We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.
Vitro Biopharma Reports Positive Clinical Trial Results of Stem Cell Activation Therapy for Autism
GOLDEN, CO / ACCESSWIRE / August 8, 2017 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro Biopharma, announced initial results of a Phase I clinical trial testing the effects of its proprietary stem ...
The report looked good to me. I don't see any reason for it being down in after hours.
Down after earnings, but I see a potential break-out and new highs
whooz yor daddy
Buy the dip: ....operating margin improved by 4.9 percentage points to 48.4%. AMGN also raises its FY17 adjusted EPS outlook to $12.15-$ 12.65 from $12-$12.60 and narrowed its revenue guidance to a range of $22.5B to $23B. The company reports adjusted EPS of $3.27 on $5.81B in sales,